Methods and systems for genetic analysis

11952,625

18/179582

March 07, 2023

This disclosure provides systems and methods for sample processing and data analysis. Sample processing may include nucleic acid sample processing and subsequent sequencing. Some or all of a nucleic acid sample may be sequenced to provide sequence information, which may be stored or otherwise maintained in an electronic storage location. The sequence information may be analyzed with the aid of a computer processor, and the analyzed sequence information may be stored in an electronic storage location that may include a pool or collection of sequence information and analyzed sequence information generated from the nucleic acid sample. Methods and systems of the present disclosure can be used, for example, for the analysis of a nucleic acid sample, for producing one or more libraries, and for producing biomedical reports. Methods and systems of the disclosure can aid in the diagnosis, monitoring, treatment, and prevention of one or more diseases and conditions.

Personalis, Inc. (Menlo Park, CA, US)

Personalis, Inc. (Fremont, CA, US)

1. A method for personalized genetic testing, comprising: (a) performing a first assay on nucleic acid molecules extracted from at least one biological sample from a subject to produce a first set of nucleic acid sequence data; (b) extracting a plurality of genetic characteristics from the first set of nucleic acid sequence data; (c) obtaining a personalized probe set for the subject, wherein; (i) the personalized probe set comprises a plurality of nucleic acid probe molecules having a plurality of nucleic acid sequences or complements thereof, and (ii) the personalized probe set comprises nucleic acid probe molecules having oligonucleotide-directed genomic content comprising: (1) at least one variable portion comprising potential neoantigen-causing variants of the subject, wherein the potential neoantigen-causing variants are identified by alignment of the first set of nucleic acid sequence data to a reference genome from the subject, and (2) at least one fixed portion selected from a group comprising one or more of (a) cancer driver genes, (b) genes involved in the pharmacogenomics of cancer drugs, (c) genes involved in Mendelian immunological diseases, (d) genes related to inherited forms of cancer, (e) genes associated with tumor escape from a targeted or immune cancer therapy, (f) HLA typing, or (g) variants common in the population and used by B-allele methods to detect structural variation; (d) performing a second assay on nucleic acid molecules extracted from one or more additional biological samples using the personalized probe set to obtain a second set of nucleic acid sequence data; and (e) outputting biomedical information of the subject based on an analysis comparing results from the first assay with results from the second assay.

2. The method of claim 1 , wherein the first assay comprises (i) exome sequencing, (ii) sequencing a panel of genes, (iii) whole genome sequencing, and/or (iv) sequencing a population of cDNA molecules derived from RNA.

3. The method of claim 1 , wherein the at least one biological sample of (a) and/or the one or more additional biological samples of (d) comprises: (i) DNA, (ii) RNA, (iii) cDNA derived from RNA, (iv) cfDNA, or (v) cfRNA.

4. The method of claim 1 , wherein the at least one biological sample of (a) comprises a plurality of biological samples.

5. The method of claim 4 , wherein the plurality of biological samples comprises: (i) DNA, (ii) RNA, (iii) cDNA derived from RNA, (iv) cfDNA, or (v) cfRNA.

6. The method of claim 4 , wherein the plurality of biological samples comprises a tumor sample and a germline sample of the subject.

7. The method of claim 6 , wherein the plurality of genetic characteristics comprises expressed genetic variants observed in the tumor sample of the subject but not observed in the germline sample of the subject.

8. The method of claim 1 , wherein the one or more additional biological samples comprises one or more blood samples.

9. The method of claim 1 , wherein the one or more additional biological samples in (d) were obtained after the at least one biological sample in (a).

10. The method of claim 1 , wherein the plurality of genetic characteristics comprises: (i) the identities and quantities of specific V(D)J sequences, or (ii) the identities of variants which may lead to immunologically active neoantigens.

11. The method of claim 1 , wherein the biomedical information comprises a biomedical report, wherein the biomedical report comprises reporting one or more biomedical outputs.

12. The method of claim 11 , further comprising providing a therapeutic intervention based on the one or more biomedical outputs.

13. The method of claim 12 , wherein the therapeutic intervention comprises an anti-cancer therapy.

14. The method of claim 13 , wherein the anti-cancer therapy comprises a cancer vaccine.

15. The method of claim 14 , wherein the cancer vaccine comprises a therapeutic vaccine or a prophylactic vaccine.

16. The method of claim 11 , wherein the one or more biomedical outputs suggest, select, designate, recommend, or otherwise determine a course of treatment and/or prevention of a disease or condition.

17. The method of claim 16 , wherein the course of treatment comprises an anti-cancer therapy.

18. The method of claim 17 , wherein the anti-cancer therapy comprises a cancer vaccine.

19. The method of claim 18 , wherein the cancer vaccine comprises a therapeutic vaccine or a prophylactic vaccine.

20. The method of claim 16 , wherein the disease or condition comprises cancer.

21. The method of claim 20 , wherein the cancer comprises recurrent cancer and/or refractory cancer.

22. The method of claim 21 , wherein the cancer comprises a sarcoma, a carcinoma, a lymphoma, or a leukemia.

23. The method of claim 11 , wherein the one or more biomedical outputs recommends modifying or continuing one or more therapies.

24. The method of claim 23 , wherein modifying one or more therapies comprises administering, initiating, reducing, increasing, and/or terminating one or more therapies.

25. The method of claim 24 , wherein the one or more therapies comprises an anti-cancer therapy.

26. The method of claim 25 , wherein the anti-cancer therapy comprises a cancer vaccine.

27. The method of claim 26 , wherein the cancer vaccine comprises a therapeutic vaccine or a prophylactic vaccine.

28. A method for personalized genetic testing, comprising: (a) performing a first assay on nucleic acid molecules extracted from at least one biological sample from a subject to produce a first set of nucleic acid sequence data; (b) extracting a plurality of genetic characteristics from the first set of nucleic acid sequence data; (c) obtaining a personalized probe set for the subject, wherein; (i) the personalized probe set comprises a plurality of nucleic acid probe molecules having a plurality of nucleic acid sequences or complements thereof, and (ii) the personalized probe set comprises nucleic acid probe molecules having oligonucleotide-directed genomic content comprising: (1) at least one variable portion comprising potential neoantigen-causing variants of the subject, wherein the potential neoantigen-causing variants are identified by alignment of the first set of nucleic acid sequence data to a reference genome from the subject, and (2) at least one fixed portion selected from a group comprising one or more of (a) cancer driver genes, (b) genes involved in the pharmacogenomics of cancer drugs, (c) genes involved in Mendelian immunological diseases, (d) genes related to inherited forms of cancer, (e) genes associated with tumor escape from a targeted or immune cancer therapy, (f) HLA typing, or (g) variants common in the population and used by B-allele methods to detect structural variation; (d) performing a second assay on nucleic acid molecules extracted from one or more additional biological samples using the personalized probe set to obtain a second set of nucleic acid sequence data; and (e) outputting biomedical information of the subject based on an analysis comparing results from the first assay with results from the second assay, wherein the biomedical information comprises one or more biomedical outputs, wherein the one or more biomedical outputs suggest, select, designate, recommend, or otherwise determine a course of treatment and/or prevention of a disease or condition, wherein the course of treatment comprises an anti-cancer therapy.

29. The method of claim 28 , wherein the anti-cancer therapy comprises a cancer vaccine.

30. The method of claim 29 , wherein the cancer vaccine comprises a therapeutic vaccine or a prophylactic vaccine.

4458066 July 1984 Caruthers et al.
4683202 July 1987 Mullis
4988617 January 1991 Landegren et al.
5143854 September 1992 Pirrung et al.
5242794 September 1993 Whiteley et al.
5299491 April 1994 Kawada
5382510 January 1995 Levine et al.
5412087 May 1995 McGall et al.
5432065 July 1995 Fuller
5472672 December 1995 Brennan
5494810 February 1996 Barany et al.
5641658 June 1997 Adams et al.
5928907 July 1999 Woudenberg et al.
6015674 January 2000 Woudenberg et al.
6045996 April 2000 Cronin et al.
6582938 June 2003 Su et al.
6754655 June 2004 Segal
6818395 November 2004 Quake et al.
7169560 January 2007 Lapidus et al.
7211390 May 2007 Rothberg et al.
7211654 May 2007 Gao et al.
7244559 July 2007 Rothberg et al.
7264929 September 2007 Rothberg et al.
7280922 October 2007 Mei et al.
7282337 October 2007 Harris
7300788 November 2007 Matsuzaki et al.
7323305 January 2008 Leamon et al.
7335762 February 2008 Rothberg et al.
7361488 April 2008 Fan et al.
7534561 May 2009 Sana et al.
7582420 September 2009 Oliphant et al.
7785783 August 2010 Morley et al.
7803550 September 2010 Makarov et al.
8026094 September 2011 Green et al.
8140270 March 2012 Kingsmore et al.
8415101 April 2013 Garner
8417459 April 2013 Reese et al.
8532930 September 2013 Rabinowitz et al.
8589175 November 2013 Glauser et al.
8785353 July 2014 Van Eijk et al.
8862410 October 2014 Hatchwell et al.
9051602 June 2015 Oliphant et al.
9109256 August 2015 Shuber
9128861 September 2015 Bartha et al.
9183496 November 2015 Harris et al.
9228232 January 2016 Faham et al.
9329170 May 2016 Clarke et al.
9416422 August 2016 Cheung
9453257 September 2016 Hoyal-Wrightson et al.
9512485 December 2016 Richardson et al.
9725755 August 2017 Poole et al.
9727692 August 2017 Harris et al.
9745626 August 2017 Bartha et al.
9909186 March 2018 Schultz
10032000 July 2018 Harris et al.
10125399 November 2018 West
10174375 January 2019 Lo et al.
10255330 March 2019 Chandratillake et al.
10262103 April 2019 Lehrer et al.
10266890 April 2019 Bartha et al.
10415091 September 2019 Bartha et al.
10450611 October 2019 West et al.
10597717 March 2020 Maguire et al.
10711306 July 2020 Shiina et al.
10738355 August 2020 Sahin et al.
10741269 August 2020 Chudova et al.
10801070 October 2020 Clement et al.
10900088 January 2021 Vogelstein et al.
11047006 June 2021 Salk et al.
11062789 July 2021 Chiu et al.
11142797 October 2021 Moynahan et al.
11155867 October 2021 Bartha et al.
11286530 March 2022 Rabinowitz et al.
11345968 May 2022 Mortimer et al.
20020006615 January 2002 Goldsborough et al.
20020164629 November 2002 Quake et al.
20030096011 May 2003 Tracy
20030099964 May 2003 Patil et al.
20030220777 November 2003 Kitchen et al.
20050042668 February 2005 Perlin
20050086035 April 2005 Peccoud et al.
20050125474 June 2005 Pednault
20050250125 November 2005 Novakoff
20050260645 November 2005 Green et al.
20060184489 August 2006 Weiner et al.
20060278241 December 2006 Ruano
20070111247 May 2007 Stephens et al.
20070184436 August 2007 Myerson et al.
20090026082 January 2009 Rothberg et al.
20090029364 January 2009 Zirwes et al.
20090127589 May 2009 Rothberg et al.
20090183268 July 2009 Kingsmore et al.
20090191565 July 2009 Lapidus et al.
20090326832 December 2009 Heckerman et al.
20100029498 February 2010 Gnirke et al.
20100035252 February 2010 Rothberg et al.
20100042438 February 2010 Moore et al.
20100137143 June 2010 Rothberg et al.
20100188073 July 2010 Rothberg et al.
20100197507 August 2010 Rothberg et al.
20100282617 November 2010 Rothberg et al.
20100300559 December 2010 Schultz et al.
20100300895 December 2010 Nobile et al.
20100301398 December 2010 Rothberg et al.
20100304982 December 2010 Hinz et al.
20110004413 January 2011 Carnevali et al.
20110009296 January 2011 Kain et al.
20110105353 May 2011 Lo et al.
20110184896 July 2011 Guyon
20120058480 March 2012 Lewis et al.
20120077682 March 2012 Bowcock et al.
20120116688 May 2012 Bhubaneswar et al.
20120143512 June 2012 Reese et al.
20120270206 October 2012 Ginns et al.
20130073217 March 2013 Dewey et al.
20130090908 April 2013 Dewey et al.
20130096011 April 2013 Rava et al.
20130124100 May 2013 Drmanac et al.
20130173177 July 2013 Pelleymounter
20130178389 July 2013 Lapidus et al.
20130296535 November 2013 Church et al.
20130311448 November 2013 Thompson
20130332081 December 2013 Reese et al.
20140200147 July 2014 Bartha et al.
20150051087 February 2015 Rabinowitz et al.
20150057160 February 2015 Breuer et al.
20160019341 January 2016 Harris et al.
20160032396 February 2016 Diehn et al.
20160041987 February 2016 Lapir et al.
20160092631 March 2016 Yandell et al.
20160122831 May 2016 West
20160283484 September 2016 Chandratillake et al.
20170166981 June 2017 Craig et al.
20170199961 July 2017 Yelensky et al.
20170253921 September 2017 Liu et al.
20170316150 November 2017 Deciu et al.
20180051338 February 2018 West et al.
20180258489 September 2018 Danenberg
20180282801 October 2018 Zhao et al.
20180363066 December 2018 Chalmers et al.
20190211406 July 2019 Babiarz et al.
20190346442 November 2019 Carr et al.
20210062258 March 2021 Bartha et al.
20210062276 March 2021 West
20210238677 August 2021 West et al.
20210398609 December 2021 Sigurjonsson et al.
20220195530 June 2022 Diehn et al.
105044108 November 2015
0281927 June 1995
1342794 September 2003
3212808 September 2017
2861788 October 2018
WO-2000018957 April 2000
WO 2005098046 October 2005
WO-2007055244 May 2007
WO 2010054589 May 2010
WO-2011050341 April 2011
WO-2011057061 May 2011
WO-2011057094 May 2011
WO-2011091046 July 2011
WO-2011160063 December 2011
WO-2011160206 December 2011
WO-2012142611 October 2012
WO-2014053295 April 2014
WO-2014062717 April 2014
WO-2014113204 July 2014
WO-2014207245 December 2014
WO-2015051275 April 2015
2015095889 June 2015
WO-2016070131 May 2016
WO-2017205823 November 2017

GB, Examination Report for GB1821178.9, dated Dec. 29, 2021. cited by applicant
GB, Search and Examination Report for GB2201571.3, dated Feb. 25, 2022. cited by applicant
EP, Extended European Search Report for EP17803719.8, dated Jan. 29, 2020. cited by applicant
WO, International Search Report and Written Opinion for PCT/US2017/034823, dated Oct. 23, 2017. cited by applicant
Adessi, et al. Solid phase DNA amplification: characterisation of primer attachment and amplification mechanisms. Nucleic Acids Res. Oct. 15, 2000;28(20):E87. cited by applicant
Akey et al., “Haplotypes vs. single marker linkage disequilibrium tests: what do we gain?”, European Journal of Human Genetics, Apr. 20, 2001, vol. 8, pp. 291-300. cited by applicant
Albert, et al. Direct selection of human genomic loci by microarray hybridization. Nat Methods. Nov. 2007;4(11):903-5. Epub Oct. 14, 2007. cited by applicant
Alter et al., “Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2,” Journal of Medical Genetics 2007;44:1-9. doi: 10.1136/jmg.2006.043257. cited by applicant
Anderson et al., “Next Generation DNA Sequencing and the Future of Genomic Medicine”, Genes 2010, 38-69; doi:10.3390/genes1010038. cited by applicant
Anonymous, “Nature Definition of Mendelian Trait”, Scitable by natureEDUCATION, 2014. cited by applicant
ARUP's product “Exome Sequencing Symptom-Guided Analysis”. http:--www.aruplab.com-guides-ug-tests-2006332.jsp. Accessed Oct. 1, 2014. cited by applicant
Asan, et al. Comprehensive comparison of three commercial human whole-exome capture platforms. Genome Biol. Sep. 28, 2011;12(9):R95. doi: 10.1186-GB-2011-12-9-r95. cited by applicant
Ausubel, et al. eds. Current Protocols in Molecular Biology. United States. Greene Publishing Associates and Wiley-Interscience. 1987. (Table of Contents). cited by applicant
Baingridge, et al. Whole exome capture in solution with 3 Gbp of data. Genome Biol. 2010;11(6):R62. doi: 10.1186-gb-2010-11-6-r62. Epub Jun. 17, 2010. cited by applicant
Baird, et al. Developing recombinant antibodies for biomarker detection. Cancer Biomark. 2010;6(5-6):271-9. doi: 10.3233-CBM-2009-0144. cited by applicant
Bamshad., “Exome sequencing as a tool for Mendelian disease gene discovery”, Nature Reviews Genetics, Nov. 2011, 12, 745-755. cited by applicant
Beck, et al. Profile of the circulating DNA in apparently healthy individuals. Clin Chem. Apr. 2009;55(4):730-8. doi: 10.1373-clinchem.2008.113597. Epub Jan. 30, 2009. cited by applicant
Behjati, et al. Genome sequencing of normal cells reveals developmental lineages and mutational processes. Nature. Sep. 18, 2014;513(7518):422-5. doi: 10.1038-nature13448. Epub Jun. 29, 2014. cited by applicant
Benesova et al., “Mutation-based detection and monitoring of cell-free tumor DNA in peripheral blood of cancer patients”, Analytical Biochemistry vol. 433, Issue 2, Feb. 15, 2013, pp. 227-234. cited by applicant
Bent, et al., “Enriching pathogen transcripts from infected samples: A capture-based approach to enhanced host-pathogen RNA sequencing”, Analytical Biochemistry, Jul. 1, 2013; vol. 438, No. 1, pp. 90-96, XP055220731, DOI: 10.1016-j.ab.2013.03.008. * abstract; pp. 91-92 “Material and Methods”. cited by applicant
Bentley, et al., “Accurate whole human genome sequencing using reversible terminator chemistry,” Nature. Nov. 6, 2008; 456(7218): 53-59. doi:10.1038/nature07517. cited by applicant
Biesecker, et al. A genomic view of mosaicism and human disease. Nat Rev Genet. May 2013;14(5):307-20. doi: 10.1038-nrg3424. cited by applicant
Bischoff, et al. Cell-free fetal DNA and intact fetal cells in maternal blood circulation: implications for first and second trimester non-invasive prenatal diagnosis. Hum Reprod Update. Nov.-Dec. 2002;8(6):493-500. cited by applicant
Blanco et al., “Highly Efficient DNA Synthesis by the Phage phi 29 DNA polymerase”, Journal of Biological Chemistry, vol. 264, No. 15, pp. 8935-8940, May 25, 1989. cited by applicant
Blaschko. The nerve distribution in the skin in their relation to the diseases of the skin: a report to the VII Congress of the German Society of Dermatology, held at Wroclaw 28-30. May 1901. (in German with English abstract). cited by applicant
Boers et al., “High-Throughput Multilocus Sequence Typing: Bringing Molecular Typing to the Next Level,” PLoS ONE 2012; 7(7):e39630. cited by applicant
Bonadona, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA. Jun. 8, 2011;305(22):2304-10. doi: 10.1001-jama.2011.743. cited by applicant
Boulesteix, et al. Evaluating microarray-based classifiers: an overview. Cancer Inform. 2008;6:77-97. Epub Feb. 29, 2008. cited by applicant
Braslavsky, et al. Sequence information can be obtained from single DNA molecules. Proc Natl Acad Sci USA. Apr. 1, 2003;100(7):3960-4. Epub Mar. 21, 2003. cited by applicant
Browne, et al. Increased promoter methylation in exfoliated breast epithelial cells in women with a previous breast biopsy. Epigenetics. Dec. 2011;6(12):1425-35. doi: 10.4161-epi.6.12.18280. cited by applicant
Brunstein., “In-depth coverage: some useful NGS terms”, Nov. 2014, Website, 1-5. cited by applicant
Bryzgunova, et al. Isolation and comparative study of cell-free nucleic acids from human urine. Ann NY Acad Sci. Sep. 2006;1075:334-40. cited by applicant
Burrell et al., “The causes and consequences of genetic heterogeneity in cancer evolution” Nature. Sep. 19, 2013;501(7467):338-45. doi: 10.1038/nature12625. cited by applicant
Carlson, et al. Decoding cell lineage from acquired mutations using arbitrary deep sequencing. Nat Methods. Nov. 27, 2011;9(1):78-80. doi: 10.1038-nmeth.1781. cited by applicant
Cell fate map adapted from the Gilberts Developmental Biology, Fourth edition, Figure 9.1. Apr. 16, 2014. http:- -biology.stackexchange.com-questions-16555-where-does-the-fate-map-of-a-human-embryo-end. cited by applicant
Chan et al., “Cancer Genome Scanning in Plasma: Detection of Tumor-Associated Copy Number Aberrations, Single-Nucleotide Variants, and Tumoral Heterogeneity by Massively Parallel Sequencing”, Clinical Chemistry 59:1, 211-224 (2013). cited by applicant
Chang, et al., Role of Bacteria in Oncogenesis. Clinical Microbiology Reviews, Oct. 2010; vol. 23 No. 4: p. 837-857. cited by applicant
Chiu, et al. Effects of blood-processing protocols on fetal and total DNA quantification in maternal plasma. Clin Chem. Sep. 2001;47(9):1607-13. cited by applicant
Choi, et al. Genetic diagnosis by whole exome capture and massively parallel DNA sequencing. Proc Natl Acad Sci U S A. Nov. 10, 2009;106(45):19096-101. doi: 10.1073-pnas.0910672106. Epub Oct. 27, 2009. cited by applicant
Clark, et al. Performance comparison of exome DNA sequencing technologies. Nat Biotechnol. Sep. 25, 2011;29(10):908-14. doi: 10.1038-nbt.1975. cited by applicant
Craig, et al. Identification of genetic variants using bar-coded multiplexed sequencing. Nat Methods. Oct. 2008;5(10):887-93. Epub Sep. 14, 2008. cited by applicant
Chu, Tianjiao et al., “Statistical model for whole genome sequencing and its application to minimally invasive diagnosis of fetal genetic disease”, Bioinformatics, vol. 25, No. 10, 2009, pp. 1244-1250. cited by applicant
Damani, et al. Characterization of circulating endothelial cells in acute myocardial infarction. Sci Transl Med. Mar. 21, 2012 ;4(126):126ra33. doi: 10.1126-scitranslmed.3003451. cited by applicant
Davies, et al., “Indications for Hematopoietic Cell Transplantation in Acute Leukemia,” Biology of Blood and Marrow Transplantation 14:154-164 (2008). doi:10.1016/j.bbmt.2007.10.024. cited by applicant
Dawe, et al. Cell migration from baby to mother. Cell Adh Migr. Jan.-Mar. 2007;1(1):19-27. Epub Jan. 28, 2007. cited by applicant
Dawson, et al., “Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer,” New England Journal of Medicine, 2013;368:1199-209; DOI:10.1056/NEJMoa1213261. Published online Mar. 13, 2013. cited by applicant
De La Chapelle. The incidence of Lynch syndrome. Fam Cancer. 2005;4(3):233-7. cited by applicant
De Mattos-Aruda et al., Circulating tumor cells and cell-free DNA as tools for managing breast cancer, Nat. Rev. Clin. Oncol 10, 377-389 (2013); published online May 28, 2013 doi:10.1038-nrclinonc.2013.80. cited by applicant
De Mattos-Aruda et al., “Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof of principle”, Annals of Oncology, vol. 25, No. 9, Jul. 9, 2014, pp. 1729-1735. cited by applicant
DeCathelineau, et al. The final step in programmed cell death: phagocytes carry apoptotic cells to the grave. Essays Biochem. 2003;39:105-17. cited by applicant
Diaz, et al. Insights into therapeutic resistance from whole-genome analyses of circulating tumor DNA. Oncotarget. Oct. 8, 2013;4(10):1856-7. cited by applicant
Diaz, et al. Liquid Biopsies: Genotyping Circulating Tumor DNA. JCO Feb. 20, 2014 vol. 32 No. 6 579-586. cited by applicant
Dressman, et al. Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci U S A. Jul. 22, 2003;100(15):8817-22. Epub Jul. 11, 2003. cited by applicant
Drmanac et al., “Human Genome Sequencing Using Unchained Base Reads on Self-Assembling DNA Nanoarrays”, Science, 327(5961), pp. 78-81, Nov. 5, 2009. cited by applicant
Lathe, R., Synthetic oligonucleotide probes deduced from amino acid sequence data: Theoretical and practical considerations. Journal of Molecular Biology, May 5, 1985; 183(1): 1-12. cited by applicant
Leamon, et al. A massively parallel PicoTiterPlate based platform for discrete picoliter-scale polymerase chain reactions. Electrophoresis. Nov. 2003; 24(21):3769-77. cited by applicant
Leary et al., “Development of Personalized Tumor Biomarkers Using Massively Parallel Sequencing”, Science Translational Medicine, Feb. 24, 2010; 2(20): 20ra14. cited by applicant
Leary, et al. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med. Nov. 28, 2012;4(162):162ra154. doi: 10.1126-scitranslmed.3004 742. cited by applicant
Levin, et al., Targeted next-generation sequencing of a cancer transcriptome enhances detection of sequence variants and novel fusion transcripts. Genome Biology, 2009. 10:R115. cited by applicant
Ley et al., “DNA Sequencing of a cytogenetically normal acute myeloid leukemia genome”, Nature, vol. 456 |Nov. 6, 2008. cited by applicant
Li et al., “The Sequence Alignment/MAP format and SAMtools”, Bioinformatics, 25(16), pp. 2078-2079, Jun. 8, 2009. cited by applicant
Li, et al., “Novel computational methods for increasing PCR primer design effectiveness in directed sequencing”, BMC Bioinformatics. Apr. 11, 2008;9:191. doi: 10.1186-1471-2105-9-191. cited by applicant
Liao et al., “Targeted Massively Parallel Sequencing of Maternal Plasma DNA Permits Efficient and Unbiased Detection of Fetal Alleles”, Clinical Chemistry 57:1, 92-101 (2011). cited by applicant
Liu, et al. Placental mosaicism for Trisomy 13: a challenge in providing the cell-free fetal DNA testing. J Assist Reprod Genet. May 2014;31(5):589-94. doi: 10.1007-s10815-014-0182-7. Epub Feb. 5, 2014. cited by applicant
Lizardi, et al. Mutation detection and single-molecule counting using isothermal rolling-circle amplification. Nat Genet. Jul. 1998;19(3):225-32. cited by applicant
Lo et al., “Presence of fetal DN in maternal plasma and serum”, Lancet 1997 350 485-87. cited by applicant
Lo, et al. Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet. Jan. 1999;64(1):218-24. cited by applicant
Lou, et al. High-throughput DNA sequencing errors are reduced by orders of magnitude using circle sequencing. Proc Natl Acad Sci U S A. Dec. 3, 2013;110(49):19872-7. doi: 10.1073-pnas.1319590110. Epub Nov. 15, 2013. cited by applicant
Lu et al., “Cancer immunotherapy targeting neoantigens”, Seminars in Immunology, Elsevier, 2016, 28, 22-27; epub Nov. 30, 2015. cited by applicant
Madeleine et al., “Comprehensive Analysis of HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 Loci and Squamous Cell Cervical Cancer Risk”, Cancer Res 2008; 68 (9), May 1, 2008. cited by applicant
Maluf et al., The Urine microRNA profile may help profile may help monitor post-transplant renal graft function, Kidney International. Jan. 1, 2014; vol. 85. No. 2: pp. 439-449. XP055442385. cited by applicant
Mamanova et al., “Target-enrichment strategies for next-generation sequencing”, Nature Methods, vol. 7, No. 2, Feb. 2010. cited by applicant
Margulies, et al. Genome sequencing in microfabricated high-density picolitre reactors. Nature. Sep. 15, 2005;437(7057):376-80. Epub Jul. 31, 2005. cited by applicant
Market, et al., V(D)J Recombination and the Evolution of the Adaptive Immune System. PLOS Biol. 2003; 1(1):e16. https:--doi.org-10.1371-journal.pbio.0000016. cited by applicant
Marsh. Pyrosequencing applications. Methods Mol Biol. 2007;373:15-24. cited by applicant
Masuzaki, et al. Detection of cell free placental DNA in maternal plasma: direct evidence from three cases of confined placental mosaicism. J Med Genet. Apr. 2004; 41 (4):289-92. cited by applicant
Mayo Clinic staff. Tests and Procedures, Urine cytology, Definition. Published Nov. 15, 2014. 3 pages. On the Mayo Clinic web site, at: http:--www.mayoclinic.org-tests-procedures-urine-cytology-basics-definition-prc-20020408. cited by applicant
Mercer, et al., Targeted sequencing for gene discovery and quantification using RNA captureSeq. Nat Protoc May 2014. vol. 9, No. 5, pp. 989-1009. Especially p. 990 col. 2 para 1, p. 990 Fig 2, p. 1991 Box 1, p. 992 col. 1 para 2. cited by applicant
Mertes et al., “Targeted enrichment of genomic DNA regions for next-generation sequencing”, Briefings in Functional Genomics, vol. 10, No. 6, 374-386, Nov. 26, 2011. cited by applicant
Michaelson, et al. Whole-genome sequencing in autism identifies hot spots for de novo germline mutation. Cell. Dec. 21, 2012;151(7):1431-42. doi: 10.1016-j.cell.2012.11.019. cited by applicant
Miller, et al., Basic concepts of microarrays and potential applications in clinical microbiology. Clinical Microbiology Reviews, Oct. 2009, p. 611-633. cited by applicant
Misawa et al., “Significance of chromosomal alterations and mutations of the N-RAS and TP53 genes in relation to leukemogenesis of acute myeloid leukemia”, Leuk Res. Jul. 1998;22(7):631-7. doi: 10.1016/s0145-2126(98)00056-3. cited by applicant
Mitra, et al. In situ localized amplification and contact replication of many individual DNA molecules. Nucleic Acids Res. Dec. 15, 1999;27(24):e34. cited by applicant
Moore, et al., Direct screening of blood by PCR and pyrosequencing for a 16S rRNA gene target from emergency department and intensive care unit patients being evaluated for bloodstream infection. Journal of clinical microbiology. Jan. 2016; 54(1): 99-105. cited by applicant
Moudrianakis, et al. Base sequence determination in nucleic acids with the electron microscope. 3. Chemistry and microscope of guanine-labeled DNA. Proc Natl Acad Sci U S A. Mar. 1965;53:564-71. cited by applicant
Muniappan, et al. The DNA polymerase beta replication error spectrum in the adenomatous polyposis coli gene contains human colon tumor mutational hotspots. Cancer Res. Jun. 1, 2002;62(11 ):3271-5. cited by applicant
Murray, et al., Improved double-stranded DNA sequencing using the linear polymerase chain reaction. Nucleic Acids Research, vol. 17, No. 21. p. 8889. Nov. 11, 1989. cited by applicant
Naxerova, et al. Hypermutable DNA chronicles the evolution of human colon cancer. Proc Natl Acad Sci U S A. May 6, 2014; 111(18):E1889-98. doi: 10.1073-pnas.1400179111. Epub Apr. 21, 2014. cited by applicant
Naxerova, et al. Using tumour phylogenetics to identify the roots of metastasis in humans. Nat Rev Clin On col. May 2015; 12(5):258-72. doi: 10.1038-nrclinonc.2014.238. Epub Jan. 20, 2015. cited by applicant
Newman et al., “An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage”, Nat Med. May 2014 ; 20(5) 548-554. doi:10.1038/nm.3519. cited by applicant
Newman et al., “An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage”, Nat Med. May 2014 ; 20(5) 548-554. Supplementary Excel Spreadsheets. cited by applicant
Newman et al., “Integrated digital error suppression for improved detection of circulating tumor DNA”, Nat Biotechnol. May 2016 ; 34(5): 547-555. doi:10.1038/nbt.3520. cited by applicant
Ng et al., “Exome sequencing identifies the cause of a mendelian disorder”, Nature Genetics, 42(1), pp. 30-35, Nov. 13, 2009. cited by applicant
Ng, et al. Targeted capture and massively parallel sequencing of 12 human exomes. Nature. Sep. 10, 2009;461(7261):272-6. doi: 10.1038-nature08250. Epub Aug. 16, 2009. cited by applicant
Novocraft. (2014). Retrieved from http:--www.novocraft.com-. cited by applicant
Nucleosome Position by MNase-seq from ENCODE-Stanford-BYU. track settings from the UC Santa Cruz Genome Browser. 2011-2012. http://hgdownload.cse.ucsc.edu-goldenPath-hg19-encodeDCC-wgEncodeSydhNsome. cited by applicant
Ochman, et al. Genetic applications of an inverse polymerase chain reaction. Genetics. Nov. 1988;120(3):621-3. cited by applicant
Ozsolak, et al. Direct RNA sequencing. Nature. Oct. 8, 2009;461(7265):814-8. doi: 10.1038-nature08390. Epub Sep. 23, 2009. cited by applicant
Park. Scientists Devise a Blood Test to Predict Heart Attack. Time Magazine. Mar. 22, 2012. 2 pages. cited by applicant
Pasaniuc, et al. Extremely low-coverage sequencing and imputation increases power for genome-wide association studies. Nat Genet. May 20, 2012;44(6):631-5. doi: 10.1038-ng.2283. With Supplementary Information. cited by applicant
Pierce, et al. Linear-after-the-exponential polymerase chain reaction and allied technologies. Real-time detection strategies for rapid, reliable diagnosis from single cells. Methods Mol Med. 2007;132:65-85. cited by applicant
Podlaha, Ondrej et al., “Evolution of the cancer genome”, Trends Genet. Apr. 2012 ; 28(4): 155-163. doi:10.1016/j.tig.2012.01.003. cited by applicant
Pritchard et al., “ColoSeq Provides Comprehensive Lynch and Polyposis Syndrome Mutational Analysis Using Massively Parallel Sequencing”, Journal of Molecular Diagnostics, vol. 14, No. 4, Jul. 2012. cited by applicant
Punnoose, et al. Molecular biomarker analyses using circulating tumor cells. PLoS One. Sep. 8, 2010;5(9):e12517. doi: 10.1371-journal.pone.0012517. cited by applicant
Ellinger et al., “The role of cell-free circulating DNA in the diagnosis and prognosis of prostate cancer”, Urologic Oncology 29:124-129 (2011), 124-129. cited by applicant
Elsharawy et al., “Accurate variant detection across non-amplified and whole genome amplified DNA using targeted next generation sequencing”, BMC Genomics 13(500), pp. 1-14, Sep. 20, 2012. cited by applicant
Elshimali, et al. The clinical utilization of circulating cell free DNA (CCFDNA) in blood of cancer patients. Int J Mol Sci. Sep. 13, 2013;14(9):18925-58. doi: 10.3390-ijms140918925. cited by applicant
Esplin et al., Personalized sequencing and the future of medicine: discovery, diagnosis and defeat of disease. Pharmacogenomics. Nov. 2014. vol. 15, Nov. 14. pp. 1771-1790. Especially p. 1772 col. 2 para 3, p. 1773 col. 1 para 3, p. 1775 col. 1 para 2, p. 1776 fig 1, p. 1777 col. 1 para 1, p. 1777 col. 2 para 2, p. 1783 col. 1 para 3, p. 1785 col. 1 para 1. cited by applicant
Fahy, et al. Self-sustained sequence replication (3SR): an isothermal transcription-based amplification system alternative to PCR. PCR Methods Appl. Aug. 1991;1 (1):25-33. cited by applicant
Fishel, et al. Meta-analysis of gene expression data: a predictor-based approach. Bioinformatics. Jul. 1, 2007;23(13):1599-606. Epub Apr. 26, 2007. cited by applicant
Forshew et al., “Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA”, Science Translational Medicine, May 30, 2012, vol. 4, Issue 136, 136ra68; DOI: 10.1126/scitranslmed.3003726. cited by applicant
Forshew et al., “Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA”, Supplementary Materials, Science Translational Medicine, May 30, 2012, vol. 4, Issue 136, 136ra68; DOI: 10.1126/scitranslmed.3003726. cited by applicant
Fox, et al. Accuracy of Next Generation Sequencing Platforms. Next Gener Seq Appl. 2014;1. pii: 1000106. cited by applicant
Freed et al. Somatic mosaicism in the human genome. Genes 5.4 (2014): 1064-1094. cited by applicant
Freshney. Culture of Animal Cells: A Manual of Basic Technique and Specialized Applications. 6th Edition. 2010. cited by applicant
Frumkin, et al. Genomic variability within an organism exposes its cell lineage tree. PLoS Comput Biol. Oct. 2005;1 (5):e50. Epub Oct. 28, 2005. cited by applicant
Gilbert, Developmental Biology. 10th ed. Published by Sinauer Associates, Inc. (Sunderland, MA). Copyright 2014. cited by applicant
Gnirke, et al. Solution Hybrid Selection with Ultra-long Oligonucleotides for Massively Parallel Targeted Sequencing. Nat. Biotechnol. (Feb. 1, 2009), 27(2):182-9. cited by applicant
Golob, Mechanisms of cell fate acquisition in the differentiation of pluripotent stem cells. Dissertation. University of Washington. 2009; 110 pages. cited by applicant
Goris; et al., “The Immunogenetic Architecture of Autoimmune Disease”, Cold Spring Harbor Perspectives in Biology, 2012, 4:a007260, 1-15. cited by applicant
Gottlieb, et al. The DiGeorge syndrome minimal critical region contains a goosecoid-like (GSCL) homeobox gene that is expressed early in human development. Am J Hum Genet. May 1997;60(5):1194-201. cited by applicant
Guo et al., “Exome sequencing generates high quality data in non-target regions”, BMC Genomics 13(194), pp. 1-10, May 20, 2012. Main text. cited by applicant
Guo et al., “Exome sequencing generates high quality data in non-target regions”, BMC Genomics 13(194), pp. 1-10, May 20, 2012. Supplementary Tables. cited by applicant
Guo et al., “Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation”, nature Genetics, Letters, vol. 45, No. 12, Dec. 2013. Published online Oct. 13, 2013. cited by applicant
Haferlach et al., “Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype”, Leukemia. Aug. 2008;22(8):1539-41. doi: 10.1038/leu.2008.143. Epub Jun. 5, 2008. cited by applicant
Hamfjord et al., Plos ONE at www.plosone.org Apr. 2012, vol. 7, Issue 4, e34150. cited by applicant
Hiratani, et al., Replication timing and transcriptional control: beyond cause and effect—part II. Curr Opin Genet Dev. Apr. 2009;19(2):142-9. doi: 10.1016-j.gde.2009.02.002. Epub Apr. 1, 2009. cited by applicant
Hirschhorn, et al. Human intersex with chromosome mosaicism of type XY-XO. Report of a case. N Engl J Med. Nov. 24, 1960;263:1044-8. cited by applicant
Holstege, et al. Somatic mutations found in the healthy blood compartment of a 115-yr-old woman demonstrate oligoclonal hematopoiesis. Genome Res. May 2014;24(5):733-42. doi: 10.1101 -gr.162131.113. Epub Apr. 23, 2014. cited by applicant
Hong, et al., Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer. Nature Communications, Apr. 1, 2015; vol. 6, No. 1: pp. 1-12. XP055501144. cited by applicant
Huang, et al. Characterization of human plasma-derived exosomal RNAs by deep sequencing. BMC Genomics. May 10, 2013;14:319. doi: 10.1186-1471-2164-14-319. cited by applicant
Human Genome Overview GRCh37. Genome Reference Consortium, Feb. 27, 2009. 1 Page. cited by applicant
Human Genome Overview GRCh37.p13. Genome Reference Consortium, Jun. 28, 2013. 2 Pages. cited by applicant
Human Genome Overview GRCh38.p12. Genome Reference Consortium, Dec. 21, 2017. 2 Pages. cited by applicant
Illumina., “Coverage Depth Recommendations”, Science and Education, 2018, Website, 1-3. cited by applicant
Illumina., “Interpreting Infinium Assay Data for Whole-Genome Structural Variation”, Technical Note: DNA Analysis, 2010. Website, 1-8. cited by applicant
Illumina Technical Note: Informatics. Sequencing coverage information methods for human whole-genome sequencing. A overview of Illumina coverage calculation methods using BaseSpace or third party analysis tools. 2014. 2 pages. cited by applicant
Illumina Technical Note: Sequencing. Estimating sequencing coverage. Before starting a sequencing experiment, you should know the depth of sequencing you want to achieve. This technical note helps you estimate that coverage. 2014. 2 pages. cited by applicant
Ito et al., “Cancer Neoantigens: A Promising Source of Immunogens for Cancer Immunotherapy”, Journal of Clinical & Cellular Immunology, Apr. 28, 2015, vol. 6, No. 2, 21559899. cited by applicant
Jenjaroenpun, et al. Characterization of RNA in exosomes secreted by human breast cancer cell lines using next-generation sequencing. PeerJ. Nov. 5, 2013;1 :e201. doi: 10.7717-peerj.201. eCollection 2013. cited by applicant
Jung et al., “Cell-free DNA in the blood as a solid tumor biomarker—A critical appraisal of the literature”, Clinica Chimica Acta 411 :1611-1624 (2010). cited by applicant
Karam, et al. Apoptosis in Carcinogenesis and Chemotherapy. Published by Springer in 2009 ISBN: 978-1-4020-9596-2. cited by applicant
Kiialainen, et al. Performance of microarray and liquid based capture methods for target enrichment for massively parallel sequencing and SNP discovery. PLoS One. Feb. 9, 2011;6(2):e16486. doi: 10.1371-journal.pone.0016486. cited by applicant
Kinde, et al. Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci US A. Jun. 7, 2011;108(23):9530-5. doi: 10.1073-pnas.1105422108. Epub May 17, 2011. cited by applicant
Koboldt et al., “VarScan: variant detection in massively parallel sequencing of individual and pooled samples”, Bioinformatics, 25(17), pp. 2283-2285, Jun. 19, 2009. cited by applicant
Kokawa, et al. Apoptosis in the human uterine endometrium during the menstrual cycle. J Clin Endocrinol Metab. Nov. 1996;81 (11):4144-7. cited by applicant
Koren, et al. Differential relationship of DNA replication timing to different forms of human mutation and variation. Am J Hum Genet. Dec. 7, 2012;91 (6):1033-40. doi: 10.1016-j.ajhg.2012.10.018. Epub Nov. 21, 2012. cited by applicant
Kosuri and Church, “Large-scale de novo DNA synthesis: technologies and applications,” Nature Methods, 11:499-507, May 2014. Available at: http:--www.nature.com-nmeth-journal-v11-n5-full-nmeth.2918.html. cited by applicant
Kothari, et al., “Emerging Technologies for Rapid Identification of Bloodstream Pathogens”, Clinical Infectious Diseases, Apr. 24, 2014:59(2);272-8). cited by applicant
Krumm et al., “Copy number variation detection and genotyping from exome sequence data”, Genome Research, 22(8), pp. 1525-1532, May 14, 2012. cited by applicant
Kuchler, et al. Buccal cells DNA extraction to obtain high quality human genomic DNA suitable for polymorphism genotyping by PCR-RFLP and Real-Time PCR. J Appl Oral Sci. Jul.-Aug. 2012;20(4):467-71. cited by applicant
Laktionov et al. “Cell-surface-bound nucleic acids: Free and cell-surface-bound nucleic acids in blood of healthy donors and breast cancer patients”, Ann. NY Acad Sci 1022:221-227 (2004). cited by applicant
Lam, et al. Time course of early and late changes in plasma DNA in trauma patients. Clin Chem. Aug. 2003;49(8):1286-91. cited by applicant
Larson et al., “SomaticSniper: identification of somatic point mutations in whole genome sequencing data”, Bioinformatics, 28(3), pp. 311-317, Dec. 6, 2011. cited by applicant
Ralph, et al., Consistency of VDJ Rearrangement and Substitution Parameters Enables Accurate B Cell Receptor Sequence Annotation. PLOS computational biology, Jan. 11, 2016; 12(1): e1004409. https:--doi.org-10.1371-journal.1004409. cited by applicant
Richter. Fecal DNA screening in colorectal cancer. Can J Gastroenterol. Jul. 2008;22(7):631-3. cited by applicant
Robinson, et al. Strategies for exome and genome sequence data analysis in disease gene discovery projects. Clinical Genetics, vol. 80, No. 2, pp. 127-132 (2011) See the whole document. cited by applicant
Robinson; et al., “The Human Phenotype Ontology: A Tool for Annotating and Analyzing Human Hereditary Disease”, The American Journal of Human Genetics, Nov. 7, 2008, 83, 610-615. cited by applicant
Rogozin, et al. Somatic mutation hotspots correlate with DNA polymerase eta error spectrum. Nat Immunol. Jun. 2001;2(6):530-6. cited by applicant
Rosenfeld, et al. Novel multi-nucleotide polymorphisms in the human genome characterized by whole genome and exome sequencing. Nucleic Acids Research, Article No. gkq408, pp. 1-10 (2010) See abstract; and pp. 8-9. cited by applicant
Ross, et al. Characterizing and measuring bias in sequence data. Genome Biology, vol. 14, No. 5, Article No. R51, pp. 1-20 (e-pub, May 29, 2013) See the whole document. cited by applicant
Ross. Introduction to Oncogenes and Molecular Cancer Medicine. Copyright 1998 Springer-Verlag New York, Inc. ISBN : 0-387-98392-9. cited by applicant
Saeys, et al. A review of feature selection techniques in bioinformatics. Bioinformatics. Oct. 1, 2007;23(19):2507-17. Epub Aug. 24, 2007. cited by applicant
Saiki, et al. Analysis of enzymatically amplified beta-globin and HLA-DQ alpha DNA with allele-specific oligonucleotide probes. Nature. Nov. 13-19, 1986;324(6093):163-6. cited by applicant
Sambrook, et al. Molecular Cloning: A Laboratory Manual. 4th Edition, 2012. cited by applicant
Samuels, et al. Genetic mosaics and the germ line lineage. Genes (Basel). Apr. 17, 2015;6(2):216-37. doi: 10.3390-genes6020216. cited by applicant
Sandri, et al. Apoptosis, DNA damage and ubiquitin expression in normal and mdx muscle fibers after exercise. FEBS Lett. Oct. 16, 1995;373(3):291-5. cited by applicant
Schmitt, et al. Detection of ultra-rare mutations by next-generation sequencing. Proc Natl Acad Sci US A. Sep. 4, 2012;109(36):14508-13. doi: 10.1073-pnas.1208715109. Epub Aug. 1, 2012. cited by applicant
Schwarzenbach, et al. Detection and monitoring of cell-free DNA in blood of patients with colorectal cancer. Ann NY Acad Sci. Aug. 2008;1137:190-6. doi: 10.1196-annals.1448.025. cited by applicant
Shaw et al. Genomic analysis of circulating cell-free DNA infers breast cancer dormancy. Genome Research 22(2):220-231 (Oct. 11, 2011). cited by applicant
Shigemizu et al., “A practical method to detect SNVs and indels from whole genome and exome sequencing data”, Scientific Reports, 3(1), pp. 1-6, Jul. 8, 2013. Main Text. cited by applicant
Shigemizu et al., “A practical method to detect SNVs and indels from whole genome and exome sequencing data”, Scientific Reports, 3(1), pp. 1-6, Jul. 8, 2013; Supplementary Information. cited by applicant
Sims et al., “Sequencing depth and coverage: key considerations in genomic analyses,” Nat Rev Genet. Feb. 2014;15(2):121-32. doi: 10.1038/nrg3642. cited by applicant
Singleton, et al. Phevor combines multiple biomedical ontologies for accurate identification of disease-causing alleles in single individuals and small nuclear families. Am J Hum Genet. Apr. 3, 2014;94(4):599-610. doi: 10.1016-j.ajhg.2014.03.010. cited by applicant
Smyth. Limma: linear models for microarray data. In: Bioinformatics and Computational Biology Solutions using R and Bioconductor. R. Gentleman, V. Carey, S. Dudoit, R. Irizarry, W. Huber (eds.), 2005, Springer, New York, pp. 397-420. cited by applicant
Snyder et al., “Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma”, Dec. 4, 2014, New England Journal of Medicine. cited by applicant
Soni, et al. Progress toward ultrafast DNA sequencing using solid-state nanopores. din Chem. Nov. 2007;53(11):1996-2001. Epub Sep. 21, 2007. cited by applicant
Spalding, et al. Retrospective birth dating of cells in humans. Cell. Jul. 15, 2005;122(1):133-43. cited by applicant
Stemmer, et al. Single-step assembly of a gene and entire plasmid from large numbers of oligodeoxyribonucleotides. Gene. Oct. 16, 1995; 164(1):49-53. cited by applicant
Stevanovic et al., Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer. Science, Apr. 14, 2017, vol. 356, No. 6334, pp. 200-205 Especially abstract, p. 1, 2, 15, Fig. S1. cited by applicant
Sudhakar, et al., Characterization of clonal immunoglobulin heavy (IGH) V-D-J gene rearrangements and the complementary-determining region in South Indian patients with precursor B-cell acute lymphoblastic leukemia. Blood Research, Mar. 2017; 52(1): 55-61. cited by applicant
Sulston, et al. Post-embryonic cell lineages of the nematode, Caenorhabditis elegans. Dev Biol. Mar. 1977;56(1):110-56. cited by applicant
Sulston, et al. The embryonic cell lineage of the nematode Caenorhabditis elegans. Dev Biol. Nov. 1983;100(1):64-119. cited by applicant
SVBio's services. http:--www.svbio.com-service-offerings-current-services. Accessed Oct. 1, 2014. cited by applicant
Swanton, Charles, “Plasma-derived Tumor DNA Analysis at Whole-Genome Resolution,” Editorials, Clinical Chemistry 59:1, 6-8; Jan. 1, 2013. cited by applicant
Teer et al., “Exome sequencing: the sweet spot before whole genomes”, Human Molecular Genetics, 19(R2), R145-R151, Aug. 12, 2010. cited by applicant
Tewhey, et al. Microdroplet-based PCR enrichment for large-scale targeted sequencing. Nat Biotechnol. Nov. 2009;27(11):1025-31. doi: 10.1038-nbt.1583. Epub Nov. 1, 2009. cited by applicant
The Human Cell Lineage Flagship Initiative. Last updated Nov. 10, 2010. 1 page. http:--www.lineage-flagsh ip.eu-. cited by applicant
Tug, et al. Exercise-induced increases in cell free DNA in human plasma originate predominantly from cells of the haematopoietic lineage. Exerc Immunol Rev. 2015;21 :164-73. cited by applicant
Turajilic et al., “Whole genome sequencing of matched primary and metastatic acral melanomas”, Genome Research, 22(2), pp. 196-207, Feb. 22, 2012. Main document. cited by applicant
Turajilic et al., “Whole genome sequencing of matched primary and metastatic acral melanomas”, Genome Research, 22(2), pp. 196-207, Feb. 22, 2012.Supplementary Figures. cited by applicant
Turajilic et al., “Whole genome sequencing of matched primary and metastatic acral melanomas”, Genome Research, 22(2), pp. 196-207, Feb. 22, 2012.Supplementary Tables. cited by applicant
Valadi, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. Jun. 2007;9(6):654-9. Epub May 7, 2007. cited by applicant
Vale et al., “Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis”, Cancer Treatment Reviews 38 (2012) 618-625. cited by applicant
Van Driel, et al. A text-mining analysis of the human phenome. Eur J Hum Genet. May 2006;14(5):535-42. cited by applicant
VarScan. (2009). Retrieved from http:--varscan.sourceforge.net-. cited by applicant
Vasan, Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation. May 16, 2006;113(19):2335-62. cited by applicant
Velculescu, et al. Characterization of the yeast transcriptome. Cell. Jan. 24, 1997;88(2):243- 51. cited by applicant
Velculescu, et al. Serial analysis of gene expression. Science. Oct. 20, 1995;270(5235):484-7. cited by applicant
Vietsch, et al., Circulating DNA and Micro-RNA in Patients with Pancreatic Cancer, Pancreat Disord Ther. Jun. 2015; 5(2): 156. doi: 10.4172-2165-7092.1000156. cited by applicant
Vinay; et al., “Immune evasion in cancer: Mechanistic basis and therapeutic strategies”, Seminars in Cancer Biology, Elsevier, 2015, 35, S185-S198. cited by applicant
Vincent, et al. Helicase-dependent isothermal DNA amplification. EMBO Rep. Aug. 2004;5(8):795-800. Epub Jul. 9, 2004. cited by applicant
Vos, et al. AFLP: a new technique for DNA fingerprinting. Nucleic Acids Res. Nov. 11, 1995;23(21):4407-14. cited by applicant
Wagle, Nikhil et al., “High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel Sequencing”, Cancer Discovery, Jan. 2012. cited by applicant
Walker, et al. Strand displacement amplification—an isothermal, in vitro DNA amplification technique. Nucleic Acids Res. Apr. 11, 1992 ;20(7):1691-6. cited by applicant
Wang, et al. Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature. Aug. 14, 2014;512(7513):155-60. doi: 10.1038-nature13600. Epub Jul. 30, 2014. cited by applicant
Wang, K. (2010). ANNOVAR Documentation. Retrieved from http:annovar.openbioinformatics.org. cited by applicant
Warren, R.L. et al., Targeted assembly of short sequence reads. PLOS One, 6(5): May 5, 2011; p. e19816, XP055347747, DOI:10.1371-journal.pone-0019816. cited by applicant
Wasserstrom, et al. Reconstruction of cell lineage trees in mice. PLoS One. Apr. 9, 2008;3(4):e1939. doi: 10.1371-journal.pone.0001939. cited by applicant
Westin, et al. Anchored multiplex amplification on a microelectronic chip array. Nat Biotechnol. Feb. 2000;18(2):199-204. cited by applicant
Xiao, et al. Identifying mRNA, microRNA and protein profiles of melanoma exosomes. PLoS One. 2012;7(10):e46874. doi: 10.1371-journal.pone.0046874. Epub Oct. 9, 2012. cited by applicant
Yang, Yaping et al., “Clinical Whole-Exome Sequencing for the Diagnosis of Mendelian Disorders”, New England Journal of Medicine, 369;16, Oct. 2, 2013. cited by applicant
Yeung et al., “LOH in the HLA Class I Region at 6p21 is Associated with Shorter Survival in Newly Diagnosed Glioblastoma”, Clinical Cancer Research, pp. 1816-1826, Apr. 1, 2013. cited by applicant
Yi et al., “Sequencing of Fifty Human Exomes Reveals Adaptation to High Altitude”, Science, 329(5987), pp. 75-78, Jul. 2, 2010. cited by applicant
Yu et al., “Mung Bean Nuclease Treatment Increases Capture Specificity of Microdroplet-PCR Based Targeted DNA Enrichment”, PLOS ONE, Jul. 24, 2014, vol. 9, No. 7, p. e103491, XP055462530, DOI: 10.1371-journal.pone.0103491. * abstract *. cited by applicant
Zeerleder. The struggle to detect circulating DNA. Crit Care. 2006;10(3):142. Epub May 16, 2006. cited by applicant
Petition for Inter-Partes Review of U.S. Pat. No. 11,299,783, IPR2023-00545, Feb. 10, 2023. cited by applicant
Petition for Inter-Partes Review of U.S. Pat. No. 10,450,611, IPR2023-00546, Feb. 10, 2023. cited by applicant
Colella et al., “QuantiSNP: an Objective Bayes Hidden-Markov Model to detect and accurately map copy number variation using SNP genotyping data,” Nucleic Acids Research, Mar. 2007, vol. 35, No. 6, pp. 2013-2025. cited by applicant
Cruz et al., “Applications of Machine Learning in Cancer Prediction and Prognosis,” Cancer Informatics, 2006, vol. 2, pp. 59-77. cited by applicant
Examination Report in EP17803719.8, dated May 30, 2023, 9 pages. cited by applicant
Fairbrother et al., “RESCUE-ESE identifies candidate exonic splicing enhancers in vertebrate exons,” Nucleic Acids Research, Jul. 1, 2004, vol. 32, pp. W187-W190. cited by applicant
Marguerat et al., “RNA Seq: from technology to biology,” Cellular and Molecular Life Sciences, 2010, vol. 67, pp. 569-579. cited by applicant
Pathak et al., “Circulating Cell-Free DNA in Plasma/Serum of Lung Cancer Patients as a Potential Screening and Prognostic Tool,” Clinical Chemistry, 2006, vol. 52, No. 10, pp. 1833-1842. cited by applicant
Chapman, et al., “Initial genome sequencing and analysis of multiple myeloma,” Nature (2011), pp. 467-472. cited by applicant
Danovi, “A sequencing revolution in cancer,” Milestones, Milestone 6, Nature, Feb. 2021, 1 page. cited by applicant
Ding, et al., “Genome remodelling in a basal-like breast cancer metastasis and xenograft,” Nature (2010), pp. 999-1005. cited by applicant
Fluidigm, Specification Sheet for Access Array™ System, Oct. 2012, 4 pages. cited by applicant
Guan, et al., “Application of next-generation sequencing in clinical oncology to advance personalized treatment of cancer,” Chinese J Cancer, Oct. 2012. 31, pp. 463-470. cited by applicant
Hohaus, et al., “Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas,” ScienceDirect, Aug. 2009 https://www.sciencedirect.com/science/article/pii/S0923753419409575, 17 pages. cited by applicant
Lee, et al., “The mutation spectrum revealed by paired genome sequences from a lung cancer patient,” May 27, 2010, pp. 473-477. cited by applicant
Khurana et al., “Integrative Annotation of Variants from 1092 Humans: Application to Cancer Genomics,” Science, Oct. 4, 2013, vol. 342, 11 pages. cited by applicant
Khurana et al., “Supporting online material for Integrative Annotation of Variants from 1092 Humans: Application to Cancer Genomics,” Science Magazine Published by American Association for the Advancement of Science, Oct. 4, 2013, vol. 342, 97 pages. cited by applicant
Office Action in CN201980050741.1, dated Nov. 22, 2023, 17 pages. cited by applicant
Office Action in JP2020-566295, dated Nov. 10, 2023, 4 pages. cited by applicant
Okosun, et al., “Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma,” Nature America (2014), 8 pages. cited by applicant
Okosun, et al., “Whole Genome Sequencing in Sequential Biopsies Reveals the Genetic Evolution of Follicular Lymphoma,” Blood (2012) 120 (21) 145, 3 pages. cited by applicant
QIAamp® DNA Mini Kit and QIAamp DNA Blood Mini Kit Handbook, Feb. 2003, 68 pages. cited by applicant
Saunders, et al., “Strelka: accurate somatic small variant calling from sequenced tumor-normal sample pairs, Bioformatics,” May 10, 2012, pp. 1811-1817. cited by applicant
Shendure et al., “Next-generation DNA sequencing,” Nat. Biotechnol. 2008, vol. 26, pp. 1135-1145. cited by applicant
Summerer et al., “Targeted high throughput sequencing of a cancer-related exome subset by specific sequence capture with a fully automated microarray platform,” Genomics, 2010, vol. 95, pp. 241-246. cited by applicant

edspgr.11952625